医药行业创新药周报（4.21-4.25）：2025年4月第四周创新药周报-20250427

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical industry as of April 27, 2025 [1]. Core Insights - The innovation drug sector in both A-shares and Hong Kong stocks saw a total of 88 stocks rise and 20 fall during the fourth week of April 2025, with notable gains from Yiming Anke-B (40.20%), Ascentage Pharma-B (38.63%), and Rongchang Bio (30.48%) [3][20]. - The A-share innovation drug sector increased by 3.82%, outperforming the CSI 300 index by 3.44 percentage points, while the biopharmaceutical sector rose by 1.17% [21]. - The Hong Kong innovation drug sector rose by 8.10%, outperforming the Hang Seng Index by 5.37 percentage points, with the Hang Seng Healthcare index increasing by 8.44% [23]. - The XBI index in the US increased by 5.64% this week, but has seen a cumulative decline of 20.73% over the past six months [4][26]. Summary by Sections Domestic Key Innovation Drug Progress - In April, one new drug was approved for market launch in China, with no new indications approved [5][42]. - The report highlights the approval of several innovative drugs in the US, including 9 NDA approvals and 2 BLA approvals in April [6][46]. Global Key Innovation Drug Transactions - A total of 16 significant transactions occurred globally this week, with notable deals including a $555 million agreement between Quanxin Bio and Caldera Therapeutics, and a$765 million agreement between Repertoire Immune and Genentech [7]. Market Performance - Over the past six months, the A-share innovation drug sector has cumulatively increased by 4.40%, outperforming the CSI 300 index by 6.70 percentage points, while the biopharmaceutical sector has declined by 7.41% [21]. - The Hong Kong innovation drug sector has seen a cumulative increase of 24.03% over the past six months, outperforming the Hang Seng Index by 7.90 percentage points [23]. Drug Development and Clinical Trials - The report details the progress of GLP-1RA drugs for diabetes and obesity, with 11 drugs approved globally for diabetes indications and 3 for obesity [14][16]. - The report also notes the ongoing clinical trials for various drugs, including those in Phase III and NDA stages [17][18].